Dana L Casey1, Yueh-Yun Chi2, Sarah S Donaldson3, Douglas S Hawkins4, Jing Tian2, Carola A Arndt5, David A Rodeberg6, Jonathan C Routh7, Timothy B Lautz8, Abha A Gupta9, Torunn I Yock10, Suzanne L Wolden1. 1. Memorial Sloan Kettering Cancer Center, New York, New York. 2. University of Florida, Gainesville, Florida. 3. Stanford University School of Medicine, Stanford, California. 4. Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington. 5. Mayo Clinic and Foundation, Rochester, Minnesota. 6. East Carolina University, Greenville, North Carolina. 7. Duke University School of Medicine, Durham, North Carolina. 8. Northwestern University, Chicago, Illinois. 9. Hospital for Sick Children, Toronto, Ontario, Canada. 10. Massachussets General Hospital, Boston, Massachusetts.
Abstract
BACKGROUND: The objective of this study was to evaluate local control for patients with intermediate-risk rhabdomyosarcoma (RMS) treated on Children's Oncology Group (COG) protocol ARST0531. METHODS: This study analyzed 424 patients with intermediate-risk RMS. Patients were randomized to chemotherapy with either vincristine, dactinomycin, and cyclophosphamide (VAC) or VAC alternating with vincristine and irinotecan. With the goal of improving local control, radiation therapy (RT) was delivered early at week 4 and was concurrent with irinotecan in the experimental arm. Individualized local control plans for children 24 months old or younger were allowed. Local failure on ARST0531 was compared with local failure on the preceding COG intermediate-risk study, D9803. RESULTS:For patients with group I/II alveolar RMS (n = 55), the 5-year cumulative incidence of local failure was 13.4%; for group III alveolar RMS (n = 141), it was 20.2%; and for group III embryonal RMS (n = 228), it was 27.9% (P = .03). Among patients with group III disease, local failure did not differ by histology, site, nodal status, RT modality, or treatment arm. Local failure was worse for a tumor size >5 cm (32.3% vs 16.7%; P = .001). Among patients with group III embryonal RMS, local failure was higher on ARST0531 than D9803 (27.9% vs 19.4%; P = .03). After the exclusion of patients 24 months old or younger or patients who did not receive radiation, local failure remained significantly increased on ARST0531 (P = .02). After adjustments for clinical prognostic factors, event-free survival and overall survival were worse on ARST0531 (P = .004 and P = .05, respectively). CONCLUSIONS: Despite interventions designed to enhance local control, local control was inferior on ARST0531 in comparison with D9803. The reason for this is unclear, but it could be the reduced cyclophosphamide dose on ARST0531.
RCT Entities:
BACKGROUND: The objective of this study was to evaluate local control for patients with intermediate-risk rhabdomyosarcoma (RMS) treated on Children's Oncology Group (COG) protocol ARST0531. METHODS: This study analyzed 424 patients with intermediate-risk RMS. Patients were randomized to chemotherapy with either vincristine, dactinomycin, and cyclophosphamide (VAC) or VAC alternating with vincristine and irinotecan. With the goal of improving local control, radiation therapy (RT) was delivered early at week 4 and was concurrent with irinotecan in the experimental arm. Individualized local control plans for children 24 months old or younger were allowed. Local failure on ARST0531 was compared with local failure on the preceding COG intermediate-risk study, D9803. RESULTS: For patients with group I/II alveolar RMS (n = 55), the 5-year cumulative incidence of local failure was 13.4%; for group III alveolar RMS (n = 141), it was 20.2%; and for group III embryonal RMS (n = 228), it was 27.9% (P = .03). Among patients with group III disease, local failure did not differ by histology, site, nodal status, RT modality, or treatment arm. Local failure was worse for a tumor size >5 cm (32.3% vs 16.7%; P = .001). Among patients with group III embryonal RMS, local failure was higher on ARST0531 than D9803 (27.9% vs 19.4%; P = .03). After the exclusion of patients 24 months old or younger or patients who did not receive radiation, local failure remained significantly increased on ARST0531 (P = .02). After adjustments for clinical prognostic factors, event-free survival and overall survival were worse on ARST0531 (P = .004 and P = .05, respectively). CONCLUSIONS: Despite interventions designed to enhance local control, local control was inferior on ARST0531 in comparison with D9803. The reason for this is unclear, but it could be the reduced cyclophosphamide dose on ARST0531.
Authors: Andrea Hayes-Jordan; Debra K Doherty; Sonlee D West; R Beverly Raney; Martin L Blakely; Charles S Cox; Richard J Andrassy; Kevin P Lally Journal: J Pediatr Surg Date: 2006-04 Impact factor: 2.545
Authors: S S Donaldson; J Meza; J C Breneman; W M Crist; F Laurie; S J Qualman; M Wharam Journal: Int J Radiat Oncol Biol Phys Date: 2001-11-01 Impact factor: 7.038
Authors: A S Pappo; J R Anderson; W M Crist; M D Wharam; P P Breitfeld; D Hawkins; R B Raney; R B Womer; D M Parham; S J Qualman; H E Grier Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544
Authors: W L Furman; C F Stewart; C A Poquette; C B Pratt; V M Santana; W C Zamboni; L C Bowman; M K Ma; F A Hoffer; W H Meyer; A S Pappo; A W Walter; P J Houghton Journal: J Clin Oncol Date: 1999-06 Impact factor: 44.544
Authors: Alberto S Pappo; Elizabeth Lyden; Phillip Breitfeld; Sarah S Donaldson; Eugene Wiener; David Parham; Kristine R Crews; Peter Houghton; William H Meyer Journal: J Clin Oncol Date: 2007-02-01 Impact factor: 44.544
Authors: David H Ilson; Manjit Bains; David P Kelsen; Eileen O'Reilly; Martin Karpeh; Daniel Coit; Valerie Rusch; Mithat Gonen; Katie Wilson; Bruce D Minsky Journal: J Clin Oncol Date: 2003-08-01 Impact factor: 44.544
Authors: Jeff M Michalski; Jane Meza; John C Breneman; Suzanne L Wolden; Fran Laurie; MaryAnn Jodoin; Beverly Raney; Moody D Wharam; Sarah S Donaldson Journal: Int J Radiat Oncol Biol Phys Date: 2004-07-15 Impact factor: 7.038
Authors: K Takeda; S Negoro; S Kudoh; K Okishio; N Masuda; M Takada; M Tanaka; T Nakajima; T Tada; M Fukuoka Journal: Br J Cancer Date: 1999-03 Impact factor: 7.640
Authors: David Boyce-Fappiano; B Ashleigh Guadagnolo; Ravin Ratan; Wei-Lien Wang; Michael J Wagner; Shreyaskumar Patel; John A Livingston; Patrick P Lin; Kevin Diao; Devarati Mitra; Ahsan Farooqi; Alexander J Lazar; Christina L Roland; Andrew J Bishop Journal: Oncologist Date: 2020-12-14
Authors: Jamie M Aye; Yueh-Yun Chi; Jing Tian; Erin R Rudzinski; Odion T Binitie; Roshni Dasgupta; Suzanne L Wolden; Douglas S Hawkins; Abha A Gupta Journal: Pediatr Blood Cancer Date: 2020-03-02 Impact factor: 3.167
Authors: Josephine H Haduong; Christine M Heske; Wendy Allen-Rhoades; Wei Xue; Lisa A Teot; David A Rodeberg; Sarah S Donaldson; Aaron Weiss; Douglas S Hawkins; Rajkumar Venkatramani Journal: Pediatr Blood Cancer Date: 2022-02-07 Impact factor: 3.167
Authors: Heidi V Russell; Yueh-Yun Chi; M Fatih Okcu; M Brooke Bernhardt; Carlos Rodriguez-Galindo; Abha A Gupta; Douglas S Hawkins Journal: Cancer Date: 2021-10-08 Impact factor: 6.860
Authors: Timothy B Lautz; Yueh-Yun Chi; Jing Tian; Abha A Gupta; Suzanne L Wolden; Jonathan C Routh; Dana L Casey; Roshni Dasgupta; Douglas S Hawkins; David A Rodeberg Journal: Int J Cancer Date: 2020-02-15 Impact factor: 7.396
Authors: Dana L Casey; Kenneth L Pitter; Leonard H Wexler; Emily K Slotkin; Gaorav P Gupta; Suzanne L Wolden Journal: Br J Cancer Date: 2021-05-20 Impact factor: 7.640
Authors: Soledad Gallego; Yueh-Yun Chi; Gian Luca De Salvo; Minjie Li; Johannes H M Merks; David A Rodeberg; Sheila Terwisscha van Scheltinga; Leo Mascarenhas; Daniel Orbach; Meriel Jenney; Lynn Million; Veronique Minard-Colin; Suzanne Wolden; Ilaria Zanetti; David M Parham; Henry Mandeville; Rajkumar Venkatramani; Gianni Bisogno; Douglas S Hawkins Journal: Pediatr Blood Cancer Date: 2020-11-27 Impact factor: 3.167